Literature DB >> 30817038

Severe asthma-A population study perspective.

Helena Backman1, Sven-Arne Jansson1, Caroline Stridsman2, Berne Eriksson3,4, Linnea Hedman1, Britt-Marie Eklund1, Thomas Sandström5, Anne Lindberg5, Bo Lundbäck1,3, Eva Rönmark1.   

Abstract

BACKGROUND: Severe asthma is a considerable challenge for patients, health-care professionals and society. Few studies have estimated the prevalence of severe asthma according to modern definitions of which none based on a population study.
OBJECTIVE: To describe characteristics and estimate the prevalence of severe asthma in a large adult population-based asthma cohort followed for 10-28 years.
METHODS: N = 1006 subjects with asthma participated in a follow-up during 2012-14, when 830 (mean age 59 years, 56% women) still had current asthma. Severe asthma was defined according to three internationally well-known criteria: the ATS workshop definition from 2000 used in the US Severe Asthma Research Programme (SARP), the 2014 ATS/ERS Task force definition and the GINA 2017. All subjects with severe asthma according to any of these criteria were undergoing respiratory specialist care and were also contacted by telephone to verify treatment adherence.
RESULTS: The prevalence of severe asthma according to the three definitions was 3.6% (US SARP), 4.8% (ERS/ATS Taskforce), and 6.1% (GINA) among subjects with current asthma. Although all were using high ICS doses and other maintenance treatment, >90% did not have controlled asthma according to the asthma control test. Severe asthma was related to age >50 years, nasal polyposis, impaired lung function, sensitization to aspergillus, and tended to be more common in women. Further, neutrophils in blood significantly discriminated severe asthma from other asthma. CONCLUSIONS AND CLINICAL RELEVANCE: Severe asthma differed significantly from other asthma in terms of demographic, clinical and inflammatory characteristics, results suggesting possibilities for improved treatment regimens of severe asthma. The prevalence of severe asthma in this asthma cohort was 4%-6%, corresponding to approximately 0.5% of the general population.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  IgE; asthma; eosinophils; epidemiology; lung function; neutrophils

Year:  2019        PMID: 30817038     DOI: 10.1111/cea.13378

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  19 in total

1.  RORγt inhibitors block both IL-17 and IL-22 conferring a potential advantage over anti-IL-17 alone to treat severe asthma.

Authors:  David Lamb; Dorothy De Sousa; Karsten Quast; Katrin Fundel-Clemens; Jonas S Erjefält; Caroline Sandén; Hans Jürgen Hoffmann; Marc Kästle; Ramona Schmid; Kevin Menden; Denis Delic
Journal:  Respir Res       Date:  2021-05-22

Review 2.  Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling.

Authors:  Grzegorz Kardas; Piotr Kuna; Michał Panek
Journal:  Front Immunol       Date:  2020-06-18       Impact factor: 7.561

Review 3.  Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.

Authors:  Celeste M Porsbjerg; Asger Sverrild; Clare M Lloyd; Andrew N Menzies-Gow; Elisabeth H Bel
Journal:  Eur Respir J       Date:  2020-11-12       Impact factor: 16.671

4.  The Swedish National Airway Register (SNAR): development, design and utility to date.

Authors:  C Stridsman; J R Konradsen; L Vanfleteren; C Pedroletti; J Binnmyr; P Edfelt; K Fjällman Schärberg; Y Sjöö; F Nyberg; A Lindberg; A Tunsäter; A Ekberg-Jansson
Journal:  Eur Clin Respir J       Date:  2020-10-23

5.  Biologics and global burden of asthma: A worldwide portrait and a call for action.

Authors:  M Caminati; M Morais-Almeida; E Bleecker; I Ansotegui; G W Canonica; C Bovo; G Senna
Journal:  World Allergy Organ J       Date:  2021-01-06       Impact factor: 4.084

6.  Specialist Perception of Severe Asthma in Korea: A Questionnaire Survey.

Authors:  Mi Ae Kim; Heung Woo Park; Byung Keun Kim; So Young Park; Ga Young Ban; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2021-05       Impact factor: 5.764

Review 7.  Allergic fungal airways disease (AFAD): an under-recognised asthma endotype.

Authors:  Catherine H Pashley; Andrew J Wardlaw
Journal:  Mycopathologia       Date:  2021-05-27       Impact factor: 2.574

8.  FEV1 decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort.

Authors:  Helena Backman; Anne Lindberg; Linnea Hedman; Caroline Stridsman; Sven-Arne Jansson; Thomas Sandström; Bo Lundbäck; Eva Rönmark
Journal:  World Allergy Organ J       Date:  2020-03-17       Impact factor: 4.084

Review 9.  Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma.

Authors:  Byung Keun Kim; So Young Park; Ga Young Ban; Mi Ae Kim; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Heung Woo Park; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

Review 10.  Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?

Authors:  Andrew Menzies-Gow; Michael E Wechsler; Chris E Brightling
Journal:  Respir Res       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.